var data={"title":"Ipratropium (oral inhalation): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ipratropium (oral inhalation): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/389795?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ipratropium-oral-inhalation-drug-information\" class=\"drug drug_general\">see &quot;Ipratropium (oral inhalation): Drug information&quot;</a> and <a href=\"topic.htm?path=ipratropium-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ipratropium (oral inhalation): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120000\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Atrovent HFA</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120001\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Ipravent Solution;</li>\n      <li>Apo-Ipravent Sterules;</li>\n      <li>Atrovent HFA;</li>\n      <li>Dom-Ipratropium;</li>\n      <li>Gen-Ipratropium;</li>\n      <li>Mylan-Ipratropium;</li>\n      <li>PHL-Ipratropium;</li>\n      <li>PMS-Ipratropium;</li>\n      <li>ratio-Ipratropium UDV;</li>\n      <li>Teva-Ipratropium Sterinebs</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10501623\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiasthmatic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Anticholinergic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Bronchodilator</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443751\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bronchopulmonary dysplasia/Respiratory distress syndrome (RDS), ventilated patients:</b>  Very limited data available; optimal dose not established. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nebulization:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-based dosing: 25 mcg/kg/dose 3 times daily. Dosing based on a placebo controlled, comparative trial in 17 preterm infants (ipratropium group, n=5;  EGA 25-29 weeks; PNA 19-103 days) with BPD and reported a significant decrease in respiratory resistance (Wilkie, 1987).     </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fixed-dosing: Some centers have used 175 mcg/dose 3 times daily administered through the ventilator circuit; dosing based on a dose range study of  10 preterm infants with BPD (EGA 24-28 weeks, PNA 18-34 days) which showed significant reduction in respiratory resistance; additional benefit observed when administered after albuterol (Brundage, 1990).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Inhalation, MDI: 4 puffs/dose every 6-8 hours delivered as either a single dose or 2 puffs every 20 minutes for 2 inhalations. In a randomized, placebo-controlled trial in preterm neonates (n=10, PNA: 1 week; EGA: 26-34 weeks) with RDS which evaluated a single 72 mcg dose [4 puffs (18 mcg/puff product used; not currently available in the U.S.)] and reported beneficial effects on blood gases and ventilator efficiency.  In another trial, which was a crossover, randomized, controlled, double-blind trial of preterm neonates (n=21, PNA: 20 &plusmn; 9 days; EGA: 27.3 &plusmn; 1.6 weeks) with RDS, a significant reduction in respiratory resistance was reported in 38% of patients after a total dose of 80 mcg [40 mcg every 20 minutes for 2 doses (20 mcg/puff product used; not currently available in the U.S.)]; higher doses [120 mcg (6 puffs)] were not shown to have additional benefit (Fayon, 2007; Lee, 1994).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10503568\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ipratropium-oral-inhalation-drug-information\" class=\"drug drug_general\">see &quot;Ipratropium (oral inhalation): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bronchospasm, wheezing:</b> Limited data available; efficacy results variable: Infants: Nebulization: 0.125-0.25 mg (125-250 mcg) every 4 hours has been found helpful in some infants with chronic or recurrent wheezing, and some patients with bronchiolitis; however, most bronchiolitis data suggests ipratropium is not effective (Hodges, 1981; Prendiville, 1987; Schuh, 1992; Stokes, 1983; Wang, 1992). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Asthma, acute exacerbation:</b> Limited data available: <b>Note:</b> Ipratropium has not been shown to provide further benefit once the patient is hospitalized (NIH guidelines, 2007): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Nebulization: 0.25-0.5 mg (250-500 mcg)  every 20 minutes for 3 doses, then as needed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Metered-dose inhaler: 4-8 puffs every 20 minutes as needed for up to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Nebulization: 0.5 mg (500 mcg) every 20 minutes for 3 doses, then as needed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Metered-dose inhaler: 8 puffs every 20 minutes as needed for up to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Asthma, maintenance (nonacute):</b> Limited data available: <b>Note:</b> Evidence is lacking that ipratropium provides added benefit to beta<sub>2</sub>-agonists in long-term control asthma therapy (GINA; 2012; NIH Guidelines, 2007): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;12 years:  </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Nebulization: 0.25-0.5 mg (250-500 mcg) every 6-8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Metered-dose inhaler: 1-2 inhalations every 6 hours; not to exceed 12 inhalations/day  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Nebulization: 0.25 mg (250 mcg) every 6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Metered-dose inhaler: 2-3 inhalations every 6 hours; maximum daily dose: 12 inhalations/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bronchospasm associated with chronic pulmonary conditions:</b> Children &ge;12 years and Adolescents: Nebulization: 0.5 mg (500 mcg, one unit-dose vial) 3-4 times daily with doses 6-8 hours apart</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Asthma exacerbation, acute</b> (NIH Asthma Guidelines, 2007): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Nebulization: 0.5 mg (500 mcg, 1 unit dose vial) every 20 minutes for 3 doses, then as needed. <b>Note:</b> Should be given in combination with a short acting beta-adrenergic agonist.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Metered-dose inhaler: 8 inhalations every 20 minutes as needed for up to 3 hours. <b>Note:</b> Should be given in combination with a short acting beta-adrenergic agonist.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bronchospasm associated with COPD: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Nebulization: 0.5 mg (500 mcg, one unit-dose vial) 3-4 times daily, with doses 6-8 hours apart</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Metered-dose inhaler: 2 inhalations 4 times daily; maximum daily dose: 12 inhalations/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling (not studied); however, dosage adjustment unlikely necessary due to low systemic absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling (not studied); however, dosage adjustment unlikely necessary due to low systemic absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120136\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol Solution, Inhalation, as bromide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Atrovent HFA: 17 mcg/actuation (12.9 g) [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Inhalation, as bromide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.02% (2.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Inhalation, as bromide [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.02% (2.5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120003\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21003347\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=ipratropium-oral-inhalation-drug-information\" class=\"drug drug_general\">see &quot;Ipratropium (oral inhalation): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Atrovent HFA 12.9 g canister contains 200 inhalations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10503569\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebulization: May be administered with or without dilution in NS; use of a nebulizer with a mouth piece, rather than a face mask, may be preferred to prevent contact with eyes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral Inhalation (metered-dose inhaler): Atrovent HFA: Prior to initial use, prime inhaler by releasing 2 test sprays into the air. If the inhaler has not been used for &gt;3 days, reprime. Avoid spraying into the eyes. Use spacer device in children &lt;8 years; use spacer device and face mask for children &le;4 years.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120058\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metered-dose inhaler: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Exposure to temperatures &gt;48&deg;C (120&deg;F) may cause bursting. Do not puncture inhaler, throw into a fire or incinerator, or use or store near heat or open flame.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebulization solution: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light. Store unused vials in foil pouch.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10501668\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebulization: Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema alone or in combination with bronchodilators (FDA approved in ages &ge;12 years and adults); has also been used to treat bronchospasm associated with asthma and as a bronchodilating agent in bronchopulmonary dysplasia and neonatal respiratory distress syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral inhalation: Atrovent HFA: Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema (FDA approved in adults); has also been used to treat bronchospasm associated with asthma  and as a bronchodilating agent in bronchopulmonary dysplasia and neonatal respiratory distress syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8117604\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Atrovent may be confused with Alupent, Serevent</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ipratropium may be confused with tiotropium</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120050\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Dysgeusia, dyspepsia, nausea, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Back pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis, cough, dyspnea, exacerbation of chronic obstructive pulmonary disease, flu-like symptoms, rhinitis, sinusitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Accommodation disturbance, acute eye pain, anaphylaxis, angioedema, bronchospasm, corneal edema, glaucoma, hypersensitivity reaction, hypotension, increased intraocular pressure, laryngospasm, palpitations, stomatitis, tachycardia, urinary retention</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120045\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to ipratropium, atropine (and its derivatives), or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120046\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchospasm: Paradoxical bronchospasm that may be life-threatening and may occur with use of inhaled bronchodilating agents; this should be distinguished from inadequate response. If paradoxical bronchospasm occurs, discontinue ipratropium and institute alternative therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May cause dizziness and blurred vision; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm, oropharyngeal edema), including anaphylaxis, have been reported. Discontinue therapy immediately if patient develops an allergic reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glaucoma: Use with caution in patients with narrow-angle glaucoma; may increase intraocular pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia/bladder neck obstruction: Use with caution in patients with prostatic hyperplasia or bladder neck obstruction; may cause urinary retention.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. Only use in acute exacerbations of asthma in conjunction with short-acting beta-adrenergic agonists for acute episodes (NAEPP 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299541\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120053\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16003&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May diminish the anticholinergic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Amifampridine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: Ipratropium (Oral Inhalation) may enhance the anticholinergic effect of Anticholinergic Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Analgesics. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120042\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120043\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120084\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Blocks the action of acetylcholine at parasympathetic sites in bronchial smooth muscle causing bronchodilation; local application to nasal mucosa inhibits serous and seromucous gland secretions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120086\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Bronchodilation: Within 15 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Metered-dose inhaler: 2 to 4 hours; Nebulization solution: 4 to 5 hours, up to 7 to 8 hours in some patients</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Not readily absorbed into the systemic circulation from the surface of the lung or from the GI tract; ~7% absorbed after nebulization of a 2 mg dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: 15% of dose reaches lower airways</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein Binding: &le;9%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Partially metabolized to inactive ester hydrolysis products</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (50%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10503584\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Atrovent&reg; HFA does not contain soya lecithin or any soy ingredients like the previous formulation did. Atrovent HFA supplies 21 mcg/puff from the valve and 17 mcg/puff from the mouthpiece. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8120138\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol solution</b> (Atrovent HFA Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">17 mcg/ACT (12.9 g): $431.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ipratropium Bromide Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.02% (2.5 mL): $1.78</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961981\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aeron (AU);</li>\n      <li>Aerotrop (AR, PY);</li>\n      <li>Aerovent (EG, IL, IQ, IR, LY, OM, YE);</li>\n      <li>Alovent (VE);</li>\n      <li>Apovent (IL);</li>\n      <li>Aproven (AU);</li>\n      <li>Atem (AE, BH, CY, EG, IQ, IR, IT, JO, KW, LB, LY, OM, PK, QA, SA, SY, YE);</li>\n      <li>Atropulm (QA);</li>\n      <li>Atrovent (AE, AR, AT, AU, BB, BD, BE, BG, BH, BR, CH, CL, CN, CO, CR, CU, CY, CZ, DK, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, HR, ID, IE, IS, JO, JP, KW, LB, LU, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, PY, QA, RU, SA, SE, SG, SK, SV, SY, TR, TW, UY);</li>\n      <li>Atrovent Aerosol (NZ);</li>\n      <li>Atrovent N (SG);</li>\n      <li>Atrovent Nasal (NZ);</li>\n      <li>Atrovent UDV (KR);</li>\n      <li>I-Patrimol (PE);</li>\n      <li>Ipragard (IE);</li>\n      <li>Ipratec (PK);</li>\n      <li>Ipravent (IN, LK);</li>\n      <li>Iprex (BD);</li>\n      <li>Ipromate (LK);</li>\n      <li>Iprovent (SG);</li>\n      <li>Midatrol (ID);</li>\n      <li>Optra (PK);</li>\n      <li>Rinatec (GB, IE);</li>\n      <li>Tropium (BD);</li>\n      <li>Tropivent (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Brundage KL Mohsini KG, Froese AB, et al. Bronchodilator response to ipratropium bromide in infants with bronchopulmonary dysplasia. <i>Am Rev Respir Dis</i>. 1990;142:1137-1142.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ipratropium-oral-inhalation-pediatric-drug-information/abstract-text/2146910/pubmed\" target=\"_blank\" id=\"2146910\">2146910</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fayon M, Tayara N, Germain C, et al. Efficacy and tolerance of high-dose inhaled ipratropium bromide vs. terbutaline in intubated premature human neonates. <i>Neonatology</i>. 2007;91:167-173.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ipratropium-oral-inhalation-pediatric-drug-information/abstract-text/17377401/pubmed\" target=\"_blank\" id=\"17377401\">17377401</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hodges IGC, Groggins RC, Milner AD, et al. Bronchodilator effect of inhaled ipratropium bromide in wheezy toddlers. <i>Arch Dis Child</i>. 1981;56(9):729-732.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ipratropium-oral-inhalation-pediatric-drug-information/abstract-text/6457571/pubmed\" target=\"_blank\" id=\"6457571\">6457571</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee H, Arnon S, Silverman M. Bronchodilator aerosol administered by metered dose inhaler and spacer in subacute neonatal respiratory distress syndrome. <i>Archives of Disease in Childhood</i>. 1994;70:218-222.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ipratropium-oral-inhalation-pediatric-drug-information/abstract-text/8198418/pubmed\" target=\"_blank\" id=\"8198418\">8198418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Institute of Health, &quot;Guidelines for the Diagnosis and Management of Asthma. NAEPP Expert Panel Report 3,&quot; August 2007. Available at: <a href=\"http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prendiville A, Green S, Silverman M. Ipratropium bromide and airways function in wheezy infants. <i>Archives of Disease in Childhood</i>. 1987;62:397-400.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ipratropium-oral-inhalation-pediatric-drug-information/abstract-text/2954510/pubmed\" target=\"_blank\" id=\"2954510\">2954510</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schuh S, Johnson DW, Callahan S, et al, &quot;Efficacy of Frequent Nebulized Ipratropium Bromide Added to Frequent High-Dose Albuterol Therapy in Severe Childhood Asthma,&quot; <i>J Pediatr</i>, 1995, 126(4):639-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ipratropium-oral-inhalation-pediatric-drug-information/abstract-text/7699549/pubmed\" target=\"_blank\" id=\"7699549\">7699549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schuh S, Johnson DW, Canny G, et al, &ldquo;Efficacy of Adding Nebulized Ipratropium Bromide to Nebulized Albuterol Therapy in Acute Bronchiolitis,&rdquo; <i>Pediatrics</i>, 1992, 90(6):920-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ipratropium-oral-inhalation-pediatric-drug-information/abstract-text/1437435/pubmed\" target=\"_blank\" id=\"1437435\">1437435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stokes GM, Milner AD, Hodges IGC, et al. Nebulized therapy in acute severe bronchitis in infancy. <i>Archives of Disease In Childhood</i>. 1983;58:279-282.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ipratropium-oral-inhalation-pediatric-drug-information/abstract-text/6221700/pubmed\" target=\"_blank\" id=\"6221700\">6221700</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang EE, Milner R, Allen U, et al, &quot;Bronchodilators for Treatment of Mild Bronchiolitis: A Factorial Randomised Trial,&quot; <i>Arch Dis Child</i>, 1992, 67(3):289-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ipratropium-oral-inhalation-pediatric-drug-information/abstract-text/1533504/pubmed\" target=\"_blank\" id=\"1533504\">1533504</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilkie RA and Bryan MH, &ldquo;Effect of Bronchodilators on Airway Resistance in Ventilator-Dependent Neonates With Chronic Lung Disease,&rdquo; <i>J Pediatr</i>, 1987, 111(2):278-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ipratropium-oral-inhalation-pediatric-drug-information/abstract-text/2956405/pubmed\" target=\"_blank\" id=\"2956405\">2956405</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16003 Version 153.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8120000\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8120001\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10501623\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11443751\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10503568\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8120136\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F8120003\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21003347\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10503569\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F8120058\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10501668\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8117604\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8120050\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8120045\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8120046\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299541\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8120053\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8120042\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8120043\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8120084\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F8120086\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F10503584\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8120138\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961981\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16003|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ipratropium-oral-inhalation-drug-information\" class=\"drug drug_general\">Ipratropium (oral inhalation): Drug information</a></li><li><a href=\"topic.htm?path=ipratropium-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">Ipratropium (oral inhalation): Patient drug information \t</a></li></ul></div></div>","javascript":null}